PLEASE REVIEW OUR PRIVACY & COOKIES NOTICE

We use cookies to collect and analyze information on site performance and usage and to ensure you can successfully navigate throughout the site.   By clicking the “ACCEPT” button to your right or by clicking on any site content, you agree to the placement of cookies on your computer.  For more information, see our Privacy Policy. 

 
Locations
 
WEBSITES
  • United States (English)
  • International (English)
  • Chinese (中文)
  • French (Français)
  • German (Deutsch)
  • Italian (Italiano)
  • Japanese (日本語)
  • Russian (Русский)
 

Leaving U.S. website

You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

YesNo
  • Investor Relations
  • LOGIN
    • Haemonetics
    • HSS Client Login
    • Software Download Center
  • REGISTER
  • Home
  • Products
     
    U.S. ProductsView International Products
    Devices
    Blood Center Devices
    • ACP 215
    • MCS+ 8150
    • MCS+ 9000
    • NexSys PCS
    • PCS 2
    Plasma Center Devices
    • NexSys PCS with Persona Technology
    • NexSys PCS with YES Technology
    • NexSys PCS
    • PCS 2
    Surgical and Diagnostic Devices
    • Cell Saver Elite+
    • Cell Saver 5+
    • Cell Saver Elite
    • TEG
    Software
    Hospital Software
    • BloodTrack
    • SafeTrace Tx
    Plasma Center Software
    • DMS
    • NexLynk DMS
    • NextGen
    Services
    Consulting Services
    • Process Improvement
     
  • Solutions
     
    Blood Management Solutions
    • Solutions for Blood Centers
    • Solutions for Hospitals
    • Solutions for Plasma Centers
     
  • Learning Center
     
    Product Training
    • All Products
    • Blood Centers
    • Hospitals
    • Plasma Centers
    Thought Leadership
    • White Papers & Clinical Reviews
    • Reference Lists
    • Poster Abstracts
    Education
       
    • About Haemonetics
       
      Company Background
      • Overview
      • Historical Timeline
      • Leadership Team
      • Scientific Advisory Council

      • Office Locations
      Investor Relations
      • Investor Relations Home
      • Stock Information
      • Earnings
      • Forecasts & Guidance
      Corporate Responsibility
      • Corporate Responsibility at Haemonetics
      Donors Make It Matter
      • Donors Make It Matter Campaign
      News & Events
      • In the News
      • Calendar of Events
      • Publications
      Careers
      • Careers Overview
      • Open Positions
      • Our Global HQ

      Grants

      • Grant Program

       
    • Customer Support

    Leaving U.S. website

    You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

    YesNo
    • Home
    • Learning Center
    • Thought Leadership
    • Poster Archives
    • Contact Us
    • Print
    • Share

    Poster Archives

    • The use and misuse of fresh frozen plasma: an analysis of 26,637 transfusion recipients

      AABB 2011

      Methods: We analyzed over three years of patient specific transfusion data from 29 US hospitals using the IMPACT Online database (Haemonetics, Braintree, MA). 26,637 patients who received 135,149 units of FFP were identified. Data was analyzed by dosage and by recipient age. View document

    • Appropriateness of red cell transfusion for patients with gastro-intestinal bleeding

      SABM 2011

      Methods: We analyzed over three years of patient specific transfusion data from 29 US hospitals using the IMPACT® Online database (Haemonetics, Braintree, MA). 13,407 patients with upper GIB and 6,772 with lower GIB who had endoscopy as part of their hospital treatment were identified. View document

    • Patterns of transfusion in obstetrical patients: information from the IMPACT® Online database

      SABM 2011

      Introduction: Little is known about current status of transfusion in obstetrical patients. We sought to understand the potential opportunities for improving blood management by analyzing transfusion data from a large number of patients having both vaginal and Caesarian deliveries. View document

    • The influence of comorbidity on red cell transfusions for patients with upper gastro-intestinal bleeding

      SABM 2011

      Methods: Final hemoglobin for patients receiving a transfusion, defined as the last recorded hemoglobin prior to discharge, was included in the analysis as an indicator of transfusion practice. We looked at age, percent transfused, units transfused, and final hemoglobin of transfused patients in separate cohorts of CCI to determine if there was a correlation between the CCI and transfusion practice. View document

    • By how much does a single unit transfusion increase the recipient’s hemoglobin?

      AABB 2010

      Methods: The effect of a single unit RBC transfusion on the recipient’s Hgb was measured in 113 patients who received only one unit of stored RBC (allogeneic or predonated autologous) during their hospital stay. Only patients who had both pre and post-transfusion measurements were included and we selected only those patients who were transfused on postoperative day 2 or 3 to eliminate the confounding variables of ongoing blood loss and/or infusion of shed blood. View document

    • Post-operative blood salvage with cell washing reduces stored blood transfusion for patients having joint replacement surgery

      SABM 2010

      Conclusion: The implementation of post-operative blood salvage with cell washing (OrthoPAT) resulted in the recovery of more than one unit of red cells per patient and reduced stored blood use by 48%. Post-operative salvage should be considered a first-line transfusion strategy in joint replacement surgery. View document

    • AABB 2010 poster abstract
    • Final hemoglobin – a proposed metric for understanding the “transfusion trigger”

      SABM 2010

      Results: As shown in the table, Hospital A’s allogeneic transfusion rate (34%) is lower than that of Hospital B (42%). The final hemoglobin metric reveals that the lower rate was achieved (at least in part) by adopting a lower hemoglobin trigger for RBC transfusion since Hospital A’s transfused patients were discharged with lower final hemoglobin values than transfused patients at Hospital B. "Over transfusion" in Hospital B is suggested by the fact that half of their transfused patients were discharged with a final hemoglobin > 10g/dL. View document

    • Contact Us
    • Terms of Use
    • Quality
    • Careers
    • Privacy Policy
    • Site Map

    © 2011-2020 Haemonetics Corporation